Neurocrine Biosciences (NBIX) Debt to Equity (2018 - 2024)
Neurocrine Biosciences' Debt to Equity history spans 6 years, with the latest figure at $0.05 for Q1 2024.
- For Q1 2024, Debt to Equity changed N/A year-over-year to $0.05; the TTM value through Mar 2024 reached $0.05, changed N/A, while the annual FY2023 figure was $0.08, 23.17% down from the prior year.
- Debt to Equity reached $0.05 in Q1 2024 per NBIX's latest filing, down from $0.08 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.53 in Q3 2020 to a low of $0.05 in Q1 2024.
- Average Debt to Equity over 4 years is $0.19, with a median of $0.1 recorded in 2022.
- The largest YoY upside for Debt to Equity was 22.53% in 2023 against a maximum downside of 23.17% in 2023.
- A 4-year view of Debt to Equity shows it stood at $0.53 in 2020, then plummeted by 81.23% to $0.1 in 2022, then fell by 23.17% to $0.08 in 2023, then tumbled by 32.47% to $0.05 in 2024.
- Per Business Quant, the three most recent readings for NBIX's Debt to Equity are $0.05 (Q1 2024), $0.08 (Q4 2023), and $0.08 (Q3 2023).